TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06720974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AquaReBal
Description: The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based RBT
Description: The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task.
Study: NCT06732765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Description: Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
Study: NCT06732583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculosis (TB) vaccine (Ad5-105K)
Description: 1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 doses of placebo on Day 0, IH

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad5-105K
Description: 1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 doses of placebo on Day 0, IH
Study: NCT06735079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL1017 (esmethadone HCI) (active drug)
Description: REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD).
Study: NCT06734039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programming of cochlear implant audio processor frequency settings
Description: Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programming of cochlear implant audio processor frequency settings
Description: Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming of cochlear implant audio processor frequency settings
Description: Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming of cochlear implant audio processor frequency settings
Description: Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software
Study: NCT06735365

Intervention type: OTHER
Intervention: CRRT
Description: Hemodiafiltration

Intervention type: OTHER
Intervention: CRRT
Description: Hemodiafiltration
Study: NCT06734130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) analog
Description: The choice of the standard of care LHRH analog will be at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Receptor Signal Inhibitor (ARSI)
Description: The choice of the standard of care ARSI will be at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.
Study: NCT06742814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Stress ball: It is a ball with moderate hardness and softness, about 6 cm, which can be held and pressed by hand.
Study: NCT06747611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin, Neomycin and MTT capsules
Description: patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
Study: NCT06747780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: A digital booklet, text messages for two weeks, and two family-based activity boosters
Study: NCT06049888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted Social Media
Description: Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
Study: NCT06747780

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control (Usual care)
Description: Control only
Study: NCT06742203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Milk-Derived EVs
Description: WPMDE1 - Whey Protein Milk-Derived EVs, is a white powder obtained by filtration, concentration, and dehydrating whey solution, with the addition of sweeteners and flavorings to balance the taste. The WPMDE1 contains a known concentration of EVs (also known as milk exosomes).
Study: NCT06750627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spinae Plane Block
Description: Catheter are placed between the erector spinae muscle and the transversus processus with ultrasound guidance, blocking the dorsal and ventral ramus from the thorax and abdominal spinal nerves, at the level of T5. Local anesthesia is injected. Drugs used are Bupivacaine 0.25% with volume of 25 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Intravenous Analgesia
Description: Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)
Study: NCT06750718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Oculus Quest 2 (OQ2) advanced 256 GB all-in-one virtual reality headset, Wi-Fi will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Sensorimotor Training
Description: An exercise program consisting of Cervical JPSM, Cervical movement sense, and Oculomotor control exercises.
Study: NCT06750679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandage
Description: A multicomponent inelastic compression bandage will be applied to the patient. Skin care and simple exercises will be added to intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage added to compression
Description: Manual lymphatic drainage will be added to multicomponent inelastik compression bandage, skin care and simple exercises
Study: NCT06755476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Counseling Program
Description: The Psychological Counseling Program consists of 8 sessions for caregivers of individuals diagnosed with Alzheimer's.~Aims of the sessions:~Session 1: Introduction, Collection of pretest data Session 2: It is aimed to inform Alzheimer's caregivers about the disease and its symptoms.~Session 3: It is aimed to strengthen caregivers' coping skills. Session 4: It is aimed to inform Alzheimer's patients about daily care practices.~Session 5: It is aimed to provide information to Alzheimer's caregivers about coping with stress.~Session 6: It is aimed to provide information about medical and financial support that individuals diagnosed with Alzheimer's and their relatives can receive in the region they live.~Session 7: It is aimed to conduct Q\&A sessions on the problems that caregivers bring.~Session 8: Collection of posttest data Sessions will be completed in 8 weeks, one day a week. Each session is planned to last approximately 60 minutes.
Study: NCT06751927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Education video on smoking, nicotine receptor involvement in addiction, craving, withdrawal and mechanisms of action for nicotine replacement and varenicline.
Study: NCT06751576

Intervention type: DEVICE
Intervention: Median LCS
Description: End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
Study: NCT06752343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol
Description: The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration
Study: NCT06752122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (in SAD)
Description: Inhalation once daily in the SAD part
Study: NCT06063642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Neurofeedback training is a type of non-invasive brain modulation technique that enables individuals to self-regulate brain activity patterns by providing them feedback on specific activity measures. Effective self-regulation is often linked to changes in cognition, behavior, and clinical symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham feedback training
Description: A controlled form of neurofeedback training that provides feedback irrelevant to the targeted mental process.
Study: NCT04994691

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Message
Description: No messages are sent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard message
Description: 2 MyChart reminders that child is overdue for well child check visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored message
Description: 2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
Study: NCT06577389

Intervention type: OTHER
Intervention: Enhanced recovery after surgery
Description: The ERAS program for lumbar fusion surgery will be implemented.
Study: NCT06578013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure ice massage
Description: * It will be used for participants in group (A), 2 cm diameter circular ice pieces will be placed inside plastic bags and covered with a thin gauze to prevent moisture transmission and direct ice contact with the skin to apply ice massage.~* Ice massage will carried out rotationally each 1 minute (30 seconds clockwise and 30 seconds counterclockwise) on L14 point for 10 minutes and on SP6 point for another 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic rocking exercises
Description: * Pelvic rocking exercise will be used for all participants in both groups (A \& B).~* Each participant will be encouraged to lie down on her back on matrix with a pillow under head then bend her knees and keep her foot flat on the floor and place one hand under curve of her back and the other hand on the top of. her abdomen then tighten buttocks and abdominal muscles simultaneously. After that each participant will be encouraged to inhale and hold (1-2-3-4) then exhale and hold 4-3-2-1 then relax muscles and feel her back flat on the underneath hand. Finally, each participant will be encouraged to repeat the last two steps about 10 times each session.~* The exercise will be repeated for 15times/ session, 3 times /week, for 3 successive menstrual cycles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic rocking exercises
Description: * Pelvic rocking exercise will be used for all participants in both groups (A \& B).~* Each participant will be encouraged to lie down on her back on matrix with a pillow under head then bend her knees and keep her foot flat on the floor and place one hand under curve of her back and the other hand on the top of. her abdomen then tighten buttocks and abdominal muscles simultaneously. After that each participant will be encouraged to inhale and hold (1-2-3-4) then exhale and hold 4-3-2-1 then relax muscles and feel her back flat on the underneath hand. Finally, each participant will be encouraged to repeat the last two steps about 10 times each session.~* The exercise will be repeated for 15times/ session, 3 times /week, for 3 successive menstrual cycles.
Study: NCT06575855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: Group A received IASTM by using Graston Tool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: METS
Description: Group B received METs
Study: NCT05827133

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06752122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCS-21 (in SAD)
Description: Inhalation once daily in the SAD part

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MAD)
Description: Inhalation once daily for seven days in the MAD part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCS-21 (in MAD)
Description: Inhalation once daily for seven days in the MAD part
Study: NCT06754722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App to guide self-acupressure
Description: The intervention is delivered via a mobile health app. EnergyPoints app, on iOS and Android, educates and guides use of acupressure rituals to self-manage fatigue and sleep disturbances. The intervention involves using the app daily for 6 weeks. A follow-along format guides correct point stimulation for two acupressure rituals (stimulating and relaxing). The app synchronizes symptom self-reports with fitness tracker (e.g., an Apple Watch or Fitbit) sleep and activity data, allowing evaluation of response to acupressure. The dashboard provides options to tailor the rituals and pressing time (½, 1 or 2 min. per point) according to symptom experience, lifestyle, and schedule. Individuals can choose to use enhancements such as aromatherapy (including an instructional safety video), relaxing music, and/or visuals during each ritual and connect with other users via the social engagement feature.
Study: NCT04881045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07257876
Description: CD47-PDL-1 bispecific antibody
Study: NCT06749639

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PUMCH-E101 Injection（Low dose）
Description: Single intravitreal injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PUMCH-E101 Injection（High dose）
Description: Single intravitreal injection
Study: NCT06756152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
Description: The most significant adverse events limiting the use of HSCT from an unrelated donor are graft-versus-host disease (GVHD) and prolonged immunodeficiency associated with the development of severe infectious complications. The use of post-transplant cyclophosphamide for the prevention of GVHD during allogeneic HSCT from unrelated and haploidentical donors has reduced the incidence of acute clinically significant GVHD in children to 25%, chronic GVHD to 12-30%, but the issue of GVHD control still remains extremely relevant. Emerging data on the use of abatacept, a selective blocker of the costimulatory signal from an antigen-presenting cell, in the prevention of intestinal GVHD and data on the effectiveness of Janus-kinase type 1/2 inhibitors (JAK-1/2) in the treatment and prevention of acute GVHD allow us to justify the use of these drugs in combination with post-transplant cyclophosphamide as a promising pharmacological platform for the prevention of GVHD.
Study: NCT06755671

Intervention type: DRUG
Intervention: Danning Tablet
Description: Danning Tablet is the only exposure in this observational study.
Study: NCT06756087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)/Vertebroplasty+Stereotactic Radiotherapy
Description: All patients received OsteoCool™ radiofrequency ablation + vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital.~Standard Control Group: Patients received SBRT (Stereotactic Body Radiation Therapy) from the Department of Radiation Oncology 2-3 weeks post-surgery. This included pre-radiation positioning, mold preparation, and radiation therapy. After radiation therapy, patients rested for 2 weeks before resuming their original anti-tumor treatment and starting follow-up.SBRT therapy was administered according to the recommendations, using one of the following dose and fractionation schemes: 4 sessions of 24 Gy, 5 sessions of 30 Gy, 6 sessions of 36 Gy, or 7 sessions of 42 Gy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Experimental
Description: patients received OsteoCool™ radiofrequency ablation+vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital. patients continued their original anti-tumor treatment within 1-2 weeks based on their recovery. No further local intervention was performed at the surgical site, and normal follow-up was started.
Study: NCT06756243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Ion Water（Shan Shang Water）
Description: Hydrogen Ion Water (also known as Hydrogen-Rich Water or Hydrogen Water) refers to water that contains dissolved hydrogen gas (H₂). Hydrogen gas is a powerful antioxidant that is believed to neutralize free radicals in the body, which may help reduce oxidative stress and improve overall health.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conventional drug therapy
Description: Based on the severity of the patient's symptoms, appropriate pharmacological treatments may include:~Mometasone Furoate Nasal Spray: Administered as 4 sprays once daily (qd). Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).~Loratadine: 10 mg taken orally once daily (qd). Montelukast Sodium: 10 mg taken orally once daily (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: Based on the severity of the patient's symptoms, appropriate pharmacological treatments may include:~Mometasone Furoate Nasal Spray: Administered as 4 sprays once daily (qd). Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).~Loratadine: 10 mg taken orally once daily (qd). Montelukast Sodium: 10 mg taken orally once daily (qd).
Study: NCT06755138

Intervention type: OTHER
Intervention: Observational Assessment
Description: This study includes the use of surface electromyography (sEMG), video analysis, and questionnaires to assess trunk compensation patterns and their relationship with scoliosis, functional, quality-of-life, and pain parameters

Intervention type: OTHER
Intervention: Observational Assessment
Description: This study includes the use of surface electromyography (sEMG), video analysis, and questionnaires to assess trunk compensation patterns and their relationship with scoliosis, functional, quality-of-life, and pain parameters
Study: NCT06754449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy group
Description: Application of different applications of art therapy such as painting, drawing, cutting to children
Study: NCT06755151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200mg
Study: NCT06754527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ON-TRAC
Description: Online tablet-based intervention that teaches youth emotion regulation skills and integrates substance use prevention content